印第安纳波利斯 - 目前市值超过7,180亿美元，交易价格高于其 InvestingPro 公允价值的礼来公司（NYSE:LLY）今日宣布，预计2024年全年收入将达到约450亿美元，较上年显著增长32%。这家制药巨头保持着令人印象深刻的80.9%的毛利率，同时预测2025年收入将在580亿美元至610亿美元之间，显示出持续的增长势头。

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its ...

Obesity continues to grab attention at the JP Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience ...

Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...

“今天的批准标志着某些阻塞性睡眠呼吸暂停患者的第一种药物治疗选择，”FDA药物评估和研究中心肺病学、过敏和重症监护部主任Sally Seymour医学博士说。“这是阻塞性睡眠呼吸暂停患者向前迈出的重要一步。” ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

据CNBC周三援引美国医疗保险与医疗补助服务中心的消息，美国消费者用于治疗睡眠呼吸暂停而购买礼来的肥胖症药物Zepbound可以被纳入医保计划Medicare。